company background image
ALNY logo

Alnylam Pharmaceuticals NasdaqGS:ALNY Stock Report

Last Price

US$144.41

Market Cap

US$18.3b

7D

-2.8%

1Y

-31.0%

Updated

20 Apr, 2024

Data

Company Financials +

ALNY Stock Overview

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

ALNY fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Alnylam Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alnylam Pharmaceuticals
Historical stock prices
Current Share PriceUS$144.41
52 Week HighUS$218.88
52 Week LowUS$143.50
Beta0.40
1 Month Change-1.51%
3 Month Change-21.53%
1 Year Change-31.00%
3 Year Change5.62%
5 Year Change65.87%
Change since IPO2,302.83%

Recent News & Updates

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Recent updates

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Mar 19
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Right But Growth Is Lacking

Is Alnylam's HELIOS-B Delay A Red Flag?

Mar 10

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Feb 18
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Just Released Its Full-Year Earnings: Here's What Analysts Think

Alnylam's Huge Opportunity

Jan 12

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Dec 18
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Price Is Out Of Tune With Revenues

Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Jun 23
Unpleasant Surprises Could Be In Store For Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shares

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Oct 25
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Weighed On By Its Debt Load?

Alnylam gets FDA nod for expanded use of rare disease drug Oxlumo

Oct 07

Alnylam: Onpattro's Position In The ATTR Amyloidosis Cardiomyopathy Market

Sep 26

Alnylam RNAi therapy for rare protein disorder gets EU approval

Sep 20

Alnylam to offer $900M convertible senior notes

Sep 12

Alnylam says trial of RNAi therapeutic cemdisiran achieves goals for IgA nephropathy

Aug 29

Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity

Aug 18

APOLLO Hits A Bullseye, And Alnylam Logs Another Major Clinical Win

Aug 04

Alnylam to target abdominal obesity after research data on gene mutation

Jul 27

Alnylam Pharmaceuticals Heading Toward A Key Trial Read-Out

Jul 19

Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Jun 21
Is Alnylam Pharmaceuticals (NASDAQ:ALNY) Using Debt In A Risky Way?

Shareholder Returns

ALNYUS BiotechsUS Market
7D-2.8%-2.5%-3.2%
1Y-31.0%-3.7%19.3%

Return vs Industry: ALNY underperformed the US Biotechs industry which returned -2.7% over the past year.

Return vs Market: ALNY underperformed the US Market which returned 20.2% over the past year.

Price Volatility

Is ALNY's price volatile compared to industry and market?
ALNY volatility
ALNY Average Weekly Movement4.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.0%

Stable Share Price: ALNY's share price has been volatile over the past 3 months.

Volatility Over Time: ALNY's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEO
20022,100Yvonne Greenstreet
Website
www.alnylam.com

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer’s disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.

Alnylam Pharmaceuticals, Inc. Fundamentals Summary

How do Alnylam Pharmaceuticals's earnings and revenue compare to its market cap?
ALNY fundamental statistics
Market capUS$18.26b
Earnings (TTM)-US$440.24m
Revenue (TTM)US$1.83b

10.0x

P/S Ratio

-41.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALNY income statement (TTM)
RevenueUS$1.83b
Cost of RevenueUS$310.41m
Gross ProfitUS$1.52b
Other ExpensesUS$1.96b
Earnings-US$440.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)-3.48
Gross Margin83.02%
Net Profit Margin-24.08%
Debt/Equity Ratio-1,086.8%

How did ALNY perform over the long term?

See historical performance and comparison